ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1928

In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C

Randy Cron1, Mingce Zhang1, Niansheng Chu2, Devin Absher3, John Bridges1, Amanda Schnell1, Anshul Vagrecha4, Shannon Lozinsky4, Suchitra Acharya4, Carolyn Levy4, Winn Chatham1 and Edward Behrens2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Pennsylvania, Philadelphia, PA, 3HudsonAlpha Institute for Biotechnology, Huntsville, AL, 4Hofstra/Northwell School of Medicine, Hempstead, NY

Meeting: ACR Convergence 2021

Keywords: Animal Model, COVID-19, genetics, macrophage activation syndrome, Natural Killer Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Abstracts: Pediatric Rheumatology – Basic Science (1927–1930)

Session Type: Abstract Session

Session Time: 3:45PM-4:00PM

Background/Purpose: Cytokine storm syndromes (CSS) are frequently fatal complications of a variety of oncologic, rheumatic, and infectious diseases. Many patients with CSS possess heterozygous missense mutations in genes related to the familial CSS, hemophagocytic lymphohistiocytosis (HLH). We recently identified missense mutations in a potentially novel CSS gene, DOCK8, among CSS patients. During the pandemic, we screened SARS-CoV-2 CSS patients (COVID-19 & MIS-C) for DOCK8 mutations, and studied the role of DOCK8 as a CSS gene using a murine model of HLH.

Methods: To date, 20 adult patients enrolled in a COVID-19 CSS clinical trial at UAB had whole genome sequencing. Four (20%) had rare heterozygous DOCK8 mutations (3 missense, 1 intronic) (Table). DOCK8 missense mutations were also identified in 6 children (UAB & Northwell) hospitalized with MIS-C (Table). DOCK8 mutations, or wild-type (WT) sequence controls, were introduced into human NK-92 cells by FOAMY virus transduction. WT and mutant DOCK8-expressing NK-92 cells were incubated with K562 target cells and compared for cytolysis and degranulation (CD107a) by flow cytometry. DOCK8 knock-out (KO) mice were compared to WT mice using an LCMV viral model of familial HLH (Jordan MB et al. Blood 2004;104:735). Following infection, mice were tracked for weight and changes in peripheral blood cell counts and cytokines as previously described (Rood JE et al. Blood 2016;127:426). After 8 days of infection, mice were euthanized and quantified for splenomegaly (weight) and liver pathology (scored by microscopy). Appropriate statistical approaches were employed for comparing nominal and ordinal data sets, respectively.

Results: Introduction of all DOCK8 missense mutations (from COVID-19 adults and children with MIS-C) into NK-92 cells resulted in diminished NK cell cytolysis and degranulation (Figure 1). In comparison to WT mice, DOCK8 KO mice displayed increased splenomegaly and prolonged weight loss (Figure 2). In addition, thrombocytopenia was statistically significantly pronounced in the DOCK8 KO mice, as was increased serum interferon-gamma (Figure 2). Histopathology revealed statistically significant liver endothelial cell activation in the DOCK8 KO mice (Figure 2).

Conclusion: DOCK8 partial dominant-negative missense mutations are present in CSS patients with COVID-19 and MIS-C and likely are risk factors for CSS development. A murine familial HLH model demonstrates a requirement for the presence of DOCK8 to prevent a hyper-inflammatory CSS-like disease state.

Table. DOCK8 mutations identified in children and adults with various cytokine storm syndromes, including COVID_19 and MIS-C.

Figure 1. Functional analyses of DOCK8 patient mutations. Human NK-92 natural killer cells were infected with FOAMY viruses expressing DOCK8 wild-type (WT) or patient missense mutations. NK-92 cells were sorted by flow cytometry based on co-expression of green fluorescent protein. LEFT: NK-92 cell lytic activity versus K562 target cells was assessed for each patient DOCK8 missense mutation and compared to control (WT). Mean percentages +/- SEM are presented relative to WT (n=3). RIGHT: Degranulation of NK-92 cells stimulated by incubation with K562 target cells was assessed for each patient DOCK8 missense mutation by detection of cell surface CD107a by flow cytometry in comparison to WT control. Mean percentages +/- SEM are presented relative to WT (n=3). Studies were conducted as previously detailed (Zhang M et al. J. Immunol. 2016;196:2492).

Figure 2. LCMV infection model of cytokine storm syndrome in DOCK8 deficient mice. Wild-type (WT) or DOCK8-/- mice were infected with LCMV as described (Rood JE et al. Blood 2016;127:426). A. Daily body weight as a percentage of initial body weight is graphed for B6 WT (closed circles) and DOCK8-/- (open circles) with means + SEM (n=9 per group). B. Splenomegaly was assessed by spleen weight after euthanization 8 days post-infection (n=9 per group). C. Platelet counts were assessed prior to (closed circles) and 8 days post-infection (open circles) for WT (left) and DOCK8-/- mice (right) (n=8 per group). D. Serum interferon-gamma levels were assessed at day 8 post-infection for WT and DOCK8-/- animals (n=10 per group). E. Endothelial cell activation was assessed by a pathology based scoring system for WT and DOCK8-/- mice (n=10 per group). F. Representative H&E stains of liver pathologic specimens for WT (left) and DOCK8-/- (right) mice 8 days after infection.


Disclosures: R. Cron, SOBI, 1, 2, 5, 6, Pfizer, 1, 5, Novartis, 2, Sironax, 2; M. Zhang, None; N. Chu, None; D. Absher, None; J. Bridges, None; A. Schnell, None; A. Vagrecha, None; S. Lozinsky, None; S. Acharya, None; C. Levy, None; W. Chatham, None; E. Behrens, None.

To cite this abstract in AMA style:

Cron R, Zhang M, Chu N, Absher D, Bridges J, Schnell A, Vagrecha A, Lozinsky S, Acharya S, Levy C, Chatham W, Behrens E. In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C

[abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/in-vitro-and-in-vivo-evidence-for-dock8-as-a-risk-allele-for-cytokine-storm-syndrome-including-covid-19-and-mis-c/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-vitro-and-in-vivo-evidence-for-dock8-as-a-risk-allele-for-cytokine-storm-syndrome-including-covid-19-and-mis-c/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology